US · Healthcare · Drug Manufacturers - General
EPS came in at 2.03 against a street estimate of 1.91 — a beat of 6.3%.
Analysts rate Gilead Sciences Inc a buy (19 buy, 11 hold, 0 sell out of 30) with an average price target of $157.15.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.59% |
| Vanguard Capital Management, LLC | 6.50% |
| FMR Inc | 5.79% |
| State Street Corp | 4.82% |
| Amvescap Plc. | 3.35% |
| Capital World Investors | 3.33% |
| Vanguard Portfolio Management, LLC | 2.83% |
| JPMorgan Chase & Co | 2.74% |
| Document | Date |
|---|---|
| Material agreement · Q2 2026 | 2026-05-20 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Results announced · Q2 2026 | 2026-05-07 |
| Shareholder vote results · Q2 2026 | 2026-05-04 |
| Reg FD disclosure · Q2 2026 | 2026-04-28 |
| Proxy statement · Q2 2026 | 2026-03-20 |
| Annual report FY2025 | 2026-02-24 |
| Quarterly report · Q3 2025 | 2025-11-07 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.82 / share ex-date Jun 15, 2026 · pay Jun 29, 2026 | 2026-06-15 |
| Dividend | $0.82 / share ex-date Mar 13, 2026 · pay Mar 30, 2026 | 2026-03-13 |
| Dividend | $0.79 / share ex-date Dec 15, 2025 · pay Dec 30, 2025 | 2025-12-15 |
| Dividend | $0.79 / share ex-date Sep 15, 2025 · pay Sep 29, 2025 | 2025-09-15 |
| Announcement | Date |
|---|---|
| Completed acquisition of Arcellx for $115 per share plus CVR Gilead Sciences completed its acquisition of Arcellx, Inc. on April 28, 2026, for approximately $7.1 billion in total consideration. The deal was announced in February 2026 and completed thr | 2026-04-28 |
| Agrees to acquire Arcellx for $115 per share plus CVR Gilead Sciences agreed to acquire Arcellx, Inc. for $115 per share in cash, plus a conditional $5 per share payment (CVR) if a specified milestone is achieved. The deal values Arcellx at app | 2026-02-23 |
| Settlement agreements resolve patent litigations, protecting drug exclusivity until 2036 Gilead Sciences announced patent settlement agreements with three generic drug manufacturers (Lupin, Cipla, and Laurus Labs) on October 6, 2025. These companies had filed to produce generic | 2025-10-06 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Gilead Sciences Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.